ImmuPharma plc (LON:IMM – Get Free Report) shares dropped 31.4% on Tuesday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. Approximately 27,337,178 shares were traded during mid-day trading, an increase of 242% from the average daily volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Stock Down 13.5%
The company’s fifty day simple moving average is GBX 10.72 and its two-hundred day simple moving average is GBX 5.88. The company has a market capitalization of £32.17 million, a price-to-earnings ratio of -7.19 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Should You Invest in Penny Stocks?
- Why Gold Loves Trump as Much as Trump Loves Gold
- How to Buy Gold Stock and Invest in Gold
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
